Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

NCT04318717 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04318717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04318717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
May 29, 2020
Completion date
July 31, 2032
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucosal melanoma of the head and neck